Roffman Miller Associates Inc. PA Sells 11,437 Shares of Aflac Incorporated (NYSE:AFL)

Roffman Miller Associates Inc. PA trimmed its position in shares of Aflac Incorporated (NYSE:AFL - Free Report) by 2.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 389,856 shares of the financial services provider's stock after selling 11,437 shares during the period. Aflac makes up approximately 2.3% of Roffman Miller Associates Inc. PA's holdings, making the stock its 17th largest holding. Roffman Miller Associates Inc. PA owned approximately 0.07% of Aflac worth $32,163,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AFL. Morgan Stanley grew its stake in shares of Aflac by 9.0% in the 3rd quarter. Morgan Stanley now owns 9,643,531 shares of the financial services provider's stock valued at $740,141,000 after purchasing an additional 794,784 shares during the period. QRG Capital Management Inc. bought a new stake in shares of Aflac in the 3rd quarter valued at approximately $47,492,000. Vanguard Group Inc. boosted its holdings in shares of Aflac by 1.1% in the 3rd quarter. Vanguard Group Inc. now owns 54,208,007 shares of the financial services provider's stock worth $4,160,465,000 after acquiring an additional 605,210 shares in the last quarter. International Assets Investment Management LLC boosted its holdings in shares of Aflac by 8,861.1% in the 4th quarter. International Assets Investment Management LLC now owns 449,849 shares of the financial services provider's stock worth $37,113,000 after acquiring an additional 444,829 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Aflac by 5.3% in the 3rd quarter. Northern Trust Corp now owns 7,295,810 shares of the financial services provider's stock worth $559,953,000 after acquiring an additional 368,704 shares in the last quarter. 67.44% of the stock is currently owned by institutional investors.

Aflac Price Performance

Shares of NYSE AFL traded down $0.15 during midday trading on Friday, reaching $83.58. 1,838,831 shares of the company were exchanged, compared to its average volume of 2,273,162. The stock's 50-day moving average price is $82.69 and its 200-day moving average price is $81.75. The stock has a market cap of $48.09 billion, a P/E ratio of 10.78, a PEG ratio of 2.31 and a beta of 0.91. Aflac Incorporated has a one year low of $64.10 and a one year high of $86.26. The company has a quick ratio of 0.06, a current ratio of 0.06 and a debt-to-equity ratio of 0.33.

Aflac (NYSE:AFL - Get Free Report) last issued its quarterly earnings results on Thursday, February 1st. The financial services provider reported $1.25 EPS for the quarter, missing analysts' consensus estimates of $1.47 by ($0.22). The business had revenue of $3.78 billion for the quarter, compared to analyst estimates of $4.44 billion. Aflac had a return on equity of 17.59% and a net margin of 24.92%. During the same quarter last year, the firm posted $1.29 EPS. On average, sell-side analysts anticipate that Aflac Incorporated will post 6.41 earnings per share for the current fiscal year.

Insider Buying and Selling at Aflac

In other news, Director Thomas J. Kenny sold 5,000 shares of the business's stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $84.62, for a total transaction of $423,100.00. Following the completion of the sale, the director now directly owns 17,920 shares of the company's stock, valued at $1,516,390.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, Director Arthur Reginald Collins sold 3,000 shares of the firm's stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $79.73, for a total transaction of $239,190.00. Following the completion of the sale, the director now owns 5,592 shares in the company, valued at approximately $445,850.16. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Thomas J. Kenny sold 5,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $84.62, for a total transaction of $423,100.00. Following the sale, the director now owns 17,920 shares of the company's stock, valued at approximately $1,516,390.40. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 46,493 shares of company stock valued at $3,765,706. Corporate insiders own 0.90% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. StockNews.com downgraded Aflac from a "hold" rating to a "sell" rating in a report on Wednesday, April 10th. Raymond James boosted their target price on Aflac from $83.00 to $88.00 and gave the stock an "outperform" rating in a report on Friday, February 2nd. Morgan Stanley boosted their target price on Aflac from $80.00 to $84.00 and gave the stock an "equal weight" rating in a report on Monday, April 15th. Wells Fargo & Company reduced their target price on Aflac from $83.00 to $81.00 and set an "equal weight" rating on the stock in a report on Thursday, April 11th. Finally, UBS Group upped their price objective on Aflac from $80.00 to $84.00 and gave the stock a "neutral" rating in a report on Wednesday, January 10th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, Aflac has a consensus rating of "Hold" and a consensus target price of $82.15.

Aflac Company Profile

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.